Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Royalty Pharma (RPRX) and Syndax Pharmaceuticals (SNDX) announced that Royalty Pharma has entered into a $350M synthetic royalty funding ...

Syndax Pharmaceuticals (SNDX) and Royalty Pharma (RPRX) announced that Syndax has entered into a $350M synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo.

The Company announced a $350 million royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo. Under the agreement, Syndax received $350 million in exchange for a 13.8% ...

GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and ...

This page features the latest news about the Syndax Pharmaceuticals share. Syndax Pharmaceuticals and Royalty Pharma Enter $350M Royalty Funding Agreement for Niktimvo Syndax Pharmaceuticals (Nasdaq: ...

About Incyte Corp and Royalty Pharma plc Incyte Corporation ... in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System ...